{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:59Z","timestamp":1792788359464,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.msard.2026.107439","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T22:26:03Z","timestamp":1786227963000},"page":"107439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prognostic effect of serum glial fibrillary acidic protein and neurofilament light chain for predicting progression independent of relapse activity in multiple sclerosis: A systematic review"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9142-8226","authenticated-orcid":false,"given":"Anoosh","family":"Maazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2026.107439_bib0029","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaneurol.2023.3997","article-title":"Neurofilament light chain elevation and disability progression in multiple sclerosis","volume":"80","author":"Abdelhak","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107439_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104662","article-title":"Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomized, double-blind phase 3 clinical trials","volume":"93","author":"Bar-Or","year":"2023","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.msard.2026.107439_bib0010","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107439_bib0021","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.27096","article-title":"Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under B-cell depleting treatment in multiple sclerosis","volume":"97","author":"Benkert","year":"2025","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107439_bib0033","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251374903","article-title":"Prognostic value of blood-based biomarkers in multiple sclerosis patients in the absence of clinical relapses or new MRI lesions","volume":"18","author":"Brummer","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"10","key":"10.1016\/j.msard.2026.107439_bib0008","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.3390\/ijms26104704","article-title":"Biomarkers of progression independent of relapse activity-can we actually measure it yet?","volume":"26","author":"Bsteh","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2026.107439_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202512946","article-title":"Assessing the relative importance of imaging and serum biomarkers in capturing disability, cognitive impairment, and clinical progression in multiple sclerosis","volume":"13","author":"Cagol","year":"2026","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.msard.2026.107439_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ana.26913","article-title":"Determinants and biomarkers of progression independent of relapses in multiple sclerosis","volume":"96","author":"Calabrese","year":"2024","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107439_bib0006","article-title":"Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis","volume":"103","author":"Ciccarelli","year":"2024","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2026.107439_bib0005","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity-free relapsing multiple sclerosis","volume":"85","author":"Cree","year":"2019","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107439_bib0017","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/jamaneurol.2024.0017","article-title":"Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis","volume":"81","author":"Cross","year":"2024","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107439_bib0009","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107439_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2025.112992","article-title":"Blood neurofilament light chain in patients with multiple sclerosis: a systematic review and updated meta-analysis","volume":"213","author":"Ebrahimi","year":"2026","journal-title":"Exp. Gerontol."},{"issue":"2","key":"10.1016\/j.msard.2026.107439_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.47588","article-title":"Serum neurofilament light and multiple sclerosis progression independent of acute inflammation","volume":"5","author":"Gafson","year":"2022","journal-title":"JAMA Netw. Open."},{"issue":"4","key":"10.1016\/j.msard.2026.107439_bib0019","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.msard.2026.107439_bib0032","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12974-025-03674-2","article-title":"Longitudinal high-frequency blood biomarkers of axonal injury and astrocytic activation after immune reconstitution in multiple sclerosis","volume":"23","author":"Inojosa","year":"2026","journal-title":"J. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.msard.2026.107439_bib0003","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107439_bib0002","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold. Spring. Harb. Perspect. Med."},{"key":"10.1016\/j.msard.2026.107439_bib0015","article-title":"PIRA should not be interpreted interchangeably with broad disability progression: comment on Solis-Tarazona et al","author":"Maazi","year":"2026","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2026.107439_bib0024","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/acn3.52187","article-title":"Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis","volume":"11","author":"Madill","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2026.107439_bib0022","article-title":"GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis","author":"Maleska Maceski","year":"2025","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.msard.2026.107439_bib0011","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107439_bib0020","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1093\/brain\/awae260","article-title":"Serum biomarkers at disease onset for personalized therapy in multiple sclerosis","volume":"147","author":"Monreal","year":"2024","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.msard.2026.107439_bib0004","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"Muller","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107439_bib0018","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2026.107439_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1477335","article-title":"Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels","volume":"15","author":"Quintanilla-Bordas","year":"2024","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107439_bib0007","first-page":"335","article-title":"Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity","volume":"44","author":"Ransohoff","year":"2023","journal-title":"Trends. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107439_bib0001","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107439_bib0012","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1007\/s00415-024-12389-y","article-title":"Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis","volume":"271","author":"Rosenstein","year":"2024","journal-title":"J. Neurol."},{"issue":"13","key":"10.1016\/j.msard.2026.107439_bib0023","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1177\/13524585251375780","article-title":"Biomarker discovery using NUcleic acid-linked immuno-sandwich assay in multiple sclerosis patients experiencing progression independent of relapse activity","volume":"31","author":"Sandgren","year":"2025","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107439_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.70395","article-title":"Dimethyl fumarate, but not rituximab, reduces serum GFAP levels and PIRMA in relapsing-remitting MS","author":"Shawket","year":"2026","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2026.107439_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106674","article-title":"Gil-Perotin S. A systematic review and meta-analysis of real-world data predictors for conversion to progressive multiple sclerosis","volume":"103","author":"Solis-Tarazona","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107439_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102870","article-title":"A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: a systematic review and meta-analysis","volume":"51","author":"Sun","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2026.107439_bib0016","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1177\/1352458521993066","article-title":"Serum neurofilament light in MS: the first true blood-based biomarker?","volume":"28","author":"Thebault","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107439_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103590","article-title":"NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study","volume":"72","author":"Uphaus","year":"2021","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.msard.2026.107439_bib0030","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/13524585231188625","article-title":"Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: an alternative to neurofilament light","volume":"29","author":"Wessels","year":"2023","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2026.107439_bib0025","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1515\/cclm-2025-1480","article-title":"Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls","volume":"64","author":"Willemse","year":"2026","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.msard.2026.107439_bib0036","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s10072-026-09187-x","article-title":"Prognostic value of neurofilament light chain protein and glial fibrillary acidic protein in multiple sclerosis subtypes and disease activity patterns: a systematic review and meta-analysis","volume":"47","author":"Yang","year":"2026","journal-title":"Neurol. Sci."}],"updated-by":[{"DOI":"10.1016\/j.msard.2026.107931","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000}},{"DOI":"10.1016\/j.msard.2026.107931","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000}}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:08:18Z","timestamp":1789369698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826004748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"alternative-id":["S2211034826004748"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107439","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic effect of serum glial fibrillary acidic protein and neurofilament light chain for predicting progression independent of relapse activity in multiple sclerosis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107439"}}